MarginsXMarginsX
Home › Markets › Health Care › TARA

Protara Therapeutics Inc. (TARA)

TARA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.38
-5.93% on the day
Market cap
$146.5M
Micro cap
Revenue
No annual revenue filed since the period ending 2014-12-31
Net income
No annual revenue filed since the period ending 2014-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerTARA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2014
SEC CIK0001359931
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials

No annual revenue filed since the period ending 2014-12-31.

Warning signs

Cash runway
4.2 months
$25.1M cash at September 30, 2026
Share count, 1 year
+59.6%
2025-11-06 to 2026-11-03 · +441.8% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$1.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$25.1M cash; operating cash flow -$18.0M a quarter.Report 2026-09-30
Shares outstanding61,570,351 (2026-11-03); 38,587,260 a year earlier; 11,364,903 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-05-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, New York, New York, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$21.7M-$18.4M$25.1MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2026
2026-06-30
Not filed-$21.7M-$15.4M$17.1MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q1 2026
2026-03-31
Not filed-$17.8M-$21.3M$14.7MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2025
2025-12-31
Not filed-$17.3M-$16.9M$49.7MNo debt tagsNeeds four quarters10-K 2026-03-10
Q3 2025
2025-09-30
Not filed-$13.3M-$12.5M$12.6MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2025
2025-06-30
Not filed-$15.0M-$12.3M$31.5MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q1 2025
2025-03-31
Not filed-$11.9M-$14.7M$91.5MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2024
2024-12-31
Not filed-$12.8M-$9.3M$162.8MNo debt tagsNeeds four quarters10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52026-05-28
Latest annual report
ANNUAL REPORT
10-K2026-03-10
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-06
Latest current report
CURRENT REPORT
8-K2026-11-06
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 812 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.0%
1 month-3.4%
3 months-35.8%
Year to date-52.5%
1 year-52.0%
From 52-week high-66.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier